COGT NASDAQ
Credit Risk of going bust: higher than 63% of companies Debt: 4.2% of company value Bonds: $38.2M held by 24 funds → details ▾
If the stock fell to about $0.23 (down 99.3%), Cogent Biosciences, Inc. would be worth roughly what it owes.
Total debt $244.3M against a stock market value of $5.55B.
Distance to default 4.01 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $113.2M (short-term plus half of long-term), stock volatility 90.6%; Altman Z'' -0.72. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Waltham, MA 02451
US
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Ferrante Karen Jean | A-Award | 759 | $31.59 | 2026-10-01 |
| Morris Arlene | S-Sale | 42,349 | $37.09 | 2026-08-27 |
| Morris Arlene | S-Sale | 3,161 | $37.54 | 2026-08-27 |
| Ferrante Karen Jean | A-Award | 627 | $38.48 | 2026-07-01 |
| Harwin Peter Evan | A-Award | 17,901 | $31.98 | 2026-06-09 |